6.2.5. general guidelines treatment prostate cancer*. recommendationsstrength ratingoffer watchful waiting (ww) policy asymptomatic patients clinically localised disease life expectancy < ten years (based comorbidities age).strongno active treatment modality shown superiority active management options deferred active treatment terms overall- pca-specific survival clinically localised low/intermediate-risk disease.stronginform patients local treatments side effects.strongsurgical treatmentinform patients surgical approach (open-, laparoscopic- robotic rp) clearly shown superiority terms functional oncological results.weakconsider avoiding nerve-sparing surgery risk ipsilateral ex-tra-capsular extension (based ct stage, isup grade group, magnetic reso-nance imaging, information combined nomogram).weakin patients undergoing lymph node dissection perform extended plnd.strongdo offer neoadjuvant androgen deprivation therapy surgery.strongradiotherapeutic treatmentoffer intensity-modulated radiation therapy (imrt) volumetric arc radiation therapy (vmat) plus image-guided radiation therapy (igrt) definitive treatment pca external-beam radiation therapy.strongoffer moderate hypofractionation (hfx) imrt/vmat plus igrt prostate patients localised disease (60 gy/20 fractions 4 weeks 70 gy/28 fractions 6 weeks).strongoffer low-dose rate (ldr) brachytherapy monotherapy patients good urinary function nccn favourable intermediate-risk disease.strongoffer ldr high-dose rate (hdr) brachytherapy boost combined imrt/vmat plus igrt patients good urinary function nccn unfa-vourable intermediate-risk high-risk disease and/or locally-advanced disease.weakactive therapeutic options outside surgery radiotherapyoffer focal therapy hifu cryotherapy within clinical trial prospective registry.strong *all recommendations based conventional imaging isotope bone scan ct/mr abdomen/pelvis. summary evidencelethe strategy based psa (at least every six months), serial dre (at least yearly) repeated biopsy. serial dre may omitted mri stable.3serial mri improve detection aggressive cancers as.a progression mri mandates repeat biopsy change treatment strategy.a stationary mri make repeat biopsy superfluous (patients low-risk tumour stable psa-d < 0.15 may excepted). recommendationsstrength ratingbase strategy active surveillance (as) strict protocol including digital rectal examination (at least yearly), prostate-specific antigen (psa) (at least every six months) repeated biopsy every 2 3 years.strongpatients low risk pca, stable mri (precise 3) stable, low psa density(< 0.15) may excused repeat biopsy.weakperform magnetic resonance imaging (mri) repeat biopsy psa rising (psa-doubling time < 3 years).strongbase change treatment biopsy progression, progression mri and/or psa.weakre-classify patients low-volume isup grade group 2 disease included protocols,if repeat non-mri-based systematic biopsies performed monitoring reveal > 3 positive cores maximum core involvement > 50%/core isup grade group 2 disease.weak